G. DAVIES, M.D., F.R.C.P.(C); P. THOMAS, M.D., F.R.C.P.(C); I. BRODER, M.D., F.R.C.P.(C); S. MINTZ, M.D., F.R.C.P.(C); F. SILVERMAN, M.Sc.; A. LEZNOFF, M.D., F.R.C.P.(C); C. TROTMAN, M.D., F.R.C.P.(C)
The efficacy of inhaled beclomethasone dipropionate has been examined in 44 steroid-dependent asthmatics observed for 9 months to 2 years. A 3-month double-blind trial found that subjects treated with beclomethasone had a significant diminution in symptoms, were able to reduce their use of medication, and had improved maximum expiratory flow rates. Approximately one half were able to discontinue the use of oral prednisone within 9 months after starting beclomethasone, and a further one third reduced their dose by at least 50%. No characteristics could be defined to predict responsiveness to beclomethasone. The effectiveness of beclomethasone was sustained for as long as 2 years and was not associated with any abnormal urine, blood, or serum values or chest X-ray findings. Candidiasis of the palate appeared in approximately one third of the subjects and was usually transient. The chronic use of beclomethasone did not result in endocrine suppression.
DAVIES G, THOMAS P, BRODER I, MINTZ S, SILVERMAN F, LEZNOFF A, et al. Steroid-Dependent Asthma Treated with Inhaled Beclomethasone Dipropionate: A Long-Term Study. Ann Intern Med. ;86:549–553. doi: 10.7326/0003-4819-86-5-549
Download citation file:
Published: Ann Intern Med. 1977;86(5):549-553.
Asthma, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use